Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Recurrent Disease 100%
• Feces microflora 66%
• Bacterial Spore 33%
• Microflora 33%
• Clinical Trial 33%
• Adverse Event 33%
• Microbiome 33%
• Gastrointestinal Symptom 33%

Medicine and Dentistry

• Recurrent Disease 100%
• Infection 100%
• Therapeutic Procedure 66%
• Adverse Event 33%
• Gastrointestinal Distress 33%
• Spore 33%
• Microbiome 33%
• Clinical Trial 33%

Immunology and Microbiology

• Bacterial Strain 50%